|  |
| --- |
| **Supplementary Table S1. Statistical methods** |
| Applied statistical method | **Details of the applied statistical method** |
| Generalized linear models (GLIMs) | <https://support.sas.com/rnd/app/stat/procedures/genmod.html>[Accessed January 22, 2021] |
| Multiple imputation (for handling missing data) | Yuan Y: Multiple imputation using SAS software. J Stat Softw 2011;45:1–25. doi:10.18637/jss.v045.i06 |
| Nonparametric survival analysis (log-rank test) | <http://www.math.wpi.edu/saspdf/stat/chap37.pdf>[Accessed January 22, 2021] |
| Generalized estimating equation (GEE) | <https://documentation.sas.com/?cdcId=pgmsascdc&cdcVersion=9.4_3.4&docsetId=statug&docsetTarget=statug_gee_syntax01.htm&locale=en>[Accessed January 22, 2021] |
| Multivariate time-to-event analysis | <https://support.sas.com/resources/papers/proceedings10/255-2010.pdf>[Accessed January 22, 2021] |

|  |
| --- |
| **Supplementary Table S2. CAILS score distribution – ITT population** |
| Response, n (%) | **Chlormethine ointment** | **Chlormethine gel** | **Total** |
| Month 1 visit |  |  |  |
| Complete response | 0 (0) | 0 (0) | 0 (0) |
| Very good partial response | 4 (3.3) | 1 (0.8) | 5 (2.1) |
| Partial response | 11 (9) | 9 (7.6) | 20 (8.3) |
| Stable disease | 78 (63.9) | 85 (72) | 163 (67.9) |
| Progressive disease | 29 (23.8) | 23 (19.5) | 52 (21.7) |
| Month 2 visit |  |  |  |
| Complete response | 2 (1.7) | 3 (2.8) | 5 (2.2) |
| Very good partial response | 7 (6) | 7 (6.5) | 14 (6.3) |
| Partial response | 19 (16.4) | 18 (16.7) | 37 (16.5) |
| Stable disease | 65 (56) | 59 (54.6) | 124 (55.4) |
| Progressive disease | 23 (19.8) | 21 (19.4) | 44 (19.6) |
| Month 3 visit |  |  |  |
| Complete response | 5 (4.5) | 4 (4.1) | 9 (4.3) |
| Very good partial response | 10 (9) | 11 (11.3) | 21 (10.1) |
| Partial response | 20 (18) | 26 (26.8) | 46 (22.1) |
| Stable disease | 60 (54.1) | 45 (46.4) | 105 (50.5) |
| Progressive disease | 16 (14.4) | 11 (11.3) | 27 (13) |
| Month 4 visit |  |  |  |
| Complete response | 9 (8.7) | 10 (10.2) | 19 (9.4) |
| Very good partial response | 12 (11.5) | 15 (15.3) | 27 (13.4) |
| Partial response | 20 (19.2) | 21 (21.4) | 41 (20.3) |
| Stable disease | 53 (51) | 44 (44.9) | 97 (48) |
| Progressive disease | 10 (9.6) | 8 (8.2) | 18 (8.9) |
| Month 5 visit |  |  |  |
| Complete response | 9 (9.2) | 13 (13.7) | 22 (11.4) |
| Very good partial response | 15 (15.3) | 14 (14.7) | 29 (15) |
| Partial response | 21 (21.4) | 25 (26.3) | 46 (23.8) |
| Stable disease | 45 (45.9) | 36 (37.9) | 81 (42) |
| Progressive disease | 8 (8.2) | 7 (7.4) | 15 (7.8) |
| Month 6 visit |  |  |  |
| Complete response | 7 (7.3) | 14 (15.6) | 21 (11.3) |
| Very good partial response | 16 (16.7) | 16 (17.8) | 32 (17.2) |
| Partial response | 21 (21.9) | 28 (31.1) | 49 (26.3) |
| Stable disease | 47 (49) | 29 (32.2) | 76 (40.9) |
| Progressive disease | 5 (5.2) | 3 (3.3) | 8 (4.3) |
| Month 8 visit |  |  |  |
| Complete response | 11 (12.2) | 14 (16.3) | 25 (14.2) |
| Very good partial response | 14 (15.6) | 18 (20.9) | 32 (18.2) |
| Partial response | 21 (23.3) | 33 (38.4) | 54 (30.7) |
| Stable disease | 39 (43.3) | 18 (20.9) | 57 (32.4) |
| Progressive disease | 5 (5.6) | 3 (3.5) | 8 (4.5) |
| Month 10 visit |  |  |  |
| Complete response | 12 (13.8) | 16 (18.6) | 28 (16.2) |
| Very good partial response | 14 (16.1) | 24 (27.9) | 38 (22) |
| Partial response | 25 (28.7) | 31 (36) | 56 (32.4) |
| Stable disease | 32 (36.8) | 10 (11.6) | 42 (24.3) |
| Progressive disease | 4 (4.6) | 5 (5.8) | 9 (5.2) |
| CAILS, Composite Assessment of Index Lesion Severity; ITT, intent-to-treat. |